TrialESMO open2023

Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study.

C Cardone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.